Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
about
Cabozantinib in the treatment of hepatocellular carcinoma.Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Targeting the value of targeted therapy.Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
P2860
Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Do the American Society of Cli ...... Construct of Clinical Benefit?
@en
Do the American Society of Cli ...... Construct of Clinical Benefit?
@nl
type
label
Do the American Society of Cli ...... Construct of Clinical Benefit?
@en
Do the American Society of Cli ...... Construct of Clinical Benefit?
@nl
prefLabel
Do the American Society of Cli ...... Construct of Clinical Benefit?
@en
Do the American Society of Cli ...... Construct of Clinical Benefit?
@nl
P2093
P356
P1476
Do the American Society of Cli ...... Construct of Clinical Benefit?
@en
P2093
Alexandra Chambers
Doreen Ezeife
Erica J McDonald
Kelley-Anne Sabarre
Kelvin K W Chan
Mahin Qureshi
Matthew C Cheung
Mona Sabharwal
P304
JCO2016716894
P356
10.1200/JCO.2016.71.6894
P407
P577
2017-06-02T00:00:00Z